News

Advances in imaging, especially radiomics and the emergence of AI and machine learning for downstream analysis are transforming lung cancer detection and management including in clinical trials. Imaging remains essential for early, often asymptomatic, lung cancer diagnosis and for accurate…   Read More

Imaging is playing an increasingly central role in prostate cancer clinical trials as therapies become more targeted and biologically driven. Molecular imaging, particularly prostate-specific membrane antigen (PSMA) PET, is redefining how disease burden, treatment response, and progression are assessed. By…   Read More

Theranostics is transforming the role of imaging in clinical trials, including those for hematologic malignancies, by aligning diagnosis and targeted treatment within the same framework. By combining molecular imaging with radioligand therapy, it not only helps identify eligible patients but…   Read More

Neuroendocrine tumors (NETs) arise in the gastroenteropancreatic system, lungs, and other sites, often at advanced stages. NETs are classified by differentiation, Ki-67, and mitotic rate, informing prognosis and therapy. A hallmark is somatostatin receptor (SSTR) expression, enabling somatostatin analogues (SSAs)…   Read More

Hepatocellular carcinoma (HCC) is not just a leading cause of cancer deaths but also has rising mortality and frequent resistance to therapy. Accurate staging and early detection directly influence eligibility for curative options and downstream outcomes. In clinical trials, integrating…   Read More

Imaging is transforming how clinicians guide cancer immunotherapy, offering visibility into immune response that was previously out of reach. CD8 PET imaging enables visualization and quantification of CD8+ T cell infiltration within tumors, a key marker of anti-tumor activity. As…   Read More

Have you ever wondered if there’s a more dynamic and accurate way to assess the efficacy of solid tumor treatments? What if you could predict the day when a patient’s tumor will double in size or shrink by half? Or…   Read More

Imaging Endpoints congratulates Anthony G. Letai, MD, PhD, on his well-deserved appointment as the 18th Director of the National Cancer Institute (NCI). Dr. Letai was sworn in on September 29, 2025, by Health and Human Services Secretary Robert F. Kennedy,…   Read More

While the Response Assessment in Neuro-Oncology (RANO) Working Group criteria have been pivotal in assessing adult high-grade gliomas, the more recently established Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria address the unique challenges of evaluating pediatric gliomas, emphasizing the need…   Read More

In clinical trials evaluating new therapies for lymphoma, the disease assessments are primarily driven by the Lugano Classification 2014 and rely heavily on PET avidity and changes in measurable disease. These objective measures are critical for standardizing evaluations and ensuring…   Read More